Comparison of propofol closed target infusion combined with remifentanil for different infusion velocities in sedative and analgesic anaesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17014193

Enrollment

Unknown

Registered

2017-12-28

Start date

2018-01-08

Completion date

Unknown

Last updated

2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plastic Surgery

Interventions

Remifentanil 5:Remifentanil 0.05µg/kg.min infusion

Remifentanil 6:Remifentanil 0.06µg/kg.min infusion

Remifentanil 7:Remifentanil 0.07µg/kg.min infusion

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. sedation and analgesia should be selected for selective operation and operation time >60min; 2. ASA grade I or II; 3. aged 18-50 years old; 4. BMI<30kg/m2; 5. Understand the informed consent and agree to sign the informed consent before the study.

Exclusion criteria

Exclusion criteria: 1. overstrain; 2. the cardiovascular, respiratory, neurological and endocrine system diseases; 3. the abnormal function of the liver and kidney; 4. the drug history of alcohol dependence; 5. the abnormal airway; 6. the hearing, intelligence and communication barriers; 7. patients can not use BIS electrode in the forehead.

Design outcomes

Primary

Measure	Time frame
BIS;Pump speed of Remifentanil;Propofol plasma target concentration;Regulation of the target concentration of propofol;percetage of BIS time in the property interval;respiratory profiles;	—

Secondary

Measure	Time frame
satisfaction of patient;intraoperative recall;	—

Countries

China

Contacts

Public ContactWenli XU

Plastic Surgery hospital(institute), CAMS, PUMC

xwllily@163.com+86 15201155646

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026